Core Insights - BioStem Technologies, Inc. has expanded its patent portfolio with 55 issued patents and 52 pending applications, emphasizing its commitment to innovation in wound care [1] - The United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for two design patents and one utility patent related to BioStem's fenestrated human placental allograft designs [2][3] - The unique design of the allografts allows for effective drainage of wound exudate while maintaining allograft area, enhancing the healing environment [2][3] Patent Details - The newly allowed patents include Design Patent Application No. 29/860,417 and No. 29/860,420, which focus on fenestrated human placental allograft designs using the BioREtain process [2] - Patent Application No. 18/926,867 covers sterile human placental allografts with multiple slits and openings, improving wound treatment efficacy, particularly for diabetic foot ulcers and dental wounds [3] Company Strategy - The CEO of BioStem Technologies highlighted the importance of these patents in advancing next-generation placental allograft technologies and reinforcing the proprietary nature of the BioREtain process [4] - The BioREtain process is designed to preserve the structural and molecular integrity of placental tissue, which is crucial for better clinical outcomes [4] Company Overview - BioStem Technologies specializes in the development, manufacturing, and commercialization of placental-derived products for advanced wound care [6] - The company’s quality management system is accredited by the American Association of Tissue Banks and adheres to current Good Tissue Practices and Good Manufacturing Processes [6]